ATNX - Athenex, Inc.
| Previous Close | 13.84 |
| Open | 13.82 |
| Bid | 14.00 x 800 |
| Ask | 13.98 x 2200 |
| Day's Range | 13.60 - 14.07 |
| 52 Week Range | 9.38 - 20.90 |
| Volume | 321,090 |
| Avg. Volume | 384,136 |
| Market Cap | 1.079B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.20 |
| Earnings Date | Mar 25, 2019 - Mar 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.20 |
- Thomson Reuters StreetEvents•4 days ago
Edited Transcript of ATNX earnings conference call or presentation 9-May-19 12:00pm GMT
Q1 2019 Athenex Inc Earnings Call
Motley Fool•17 days agoAthenex, Inc. (ATNX) Q1 2019 Earnings Call Transcript
ATNX earnings call for the period ending March 31, 2019.
- Associated Press•17 days ago
Athenex: 1Q Earnings Snapshot
On a per-share basis, the Buffalo, New York-based company said it had a loss of 53 cents. The biopharmaceutical company posted revenue of $25.3 million in the period. Athenex shares have risen slightly ...
Motley Fool•20 days agoWhy Bausch Health Companies, Aquantia, and Athenex Jumped Today
Despite pressure on the broader market, these stocks bucked the downtrend.
- American City Business Journals•20 days ago
Athenex just raised $100 million. Here's what it means
Two major healthcare investment entities are investing $100 million in Athenex, a potential sign of things to come.
- GlobeNewswire•20 days ago
Athenex Announces $100 Million Private Placement
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has directly entered into an agreement for the sale of its common stock in a private placement with three institutional investors, namely Perceptive Advisors, Avoro Capital Advisors (formerly known as venBio Select Advisor) and OrbiMed. The transaction is expected to result in gross proceeds to Athenex of approximately $100 million, before deducting offering expenses.
- Insider Monkey•21 days ago
Hedge Funds Have Never Been This Bullish On Athenex, Inc. (ATNX)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the market. Hedge […]
- GlobeNewswire•23 days ago
Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma
BUFFALO, N.Y., May 03, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies.
- GlobeNewswire•last month
Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019
BUFFALO, N.Y., April 25, 2019 -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•last month
Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
BUFFALO, N.Y., April 23, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•2 months ago
Athenex Announces Appointment of John Koh as a New Board Member
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of John Koh as a Director on Athenex’s Board, effective April 1, 2019. Mr. Koh joins the Company’s expanded Board of Directors together with recently announced additions of Dr. John Vierling, Ms. Stephanie Davis and Mr. Jordan Kanfer.
- GuruFocus.com•2 months ago
Weekly CEO Buys Highlight
Details the CEO buys this past week for the following companies: Continental Resources, New Fortress Energy, Athenex, FS KKR Capital and Federal Agricultural Mortgage
- GlobeNewswire•2 months ago
Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Jordan S. Kanfer, Managing Director, Convertible and Equity Research at Opti Capital Management, to its Board of Directors, effective April 1, 2019. Mr. Kanfer will replace SongYi Zhang, J.D., who is stepping down.
- GuruFocus.com•2 months ago
Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The price of the stock has decreased by 0.16% since.
- GlobeNewswire•2 months ago
Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited
BUFFALO, N.Y., March 28, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•2 months ago
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Athenex Announces Xiangxue Life Sciences Receives IND Allowance from China’s National Medical Products Administration for Cancer Immunotherapy Drug Candidate
This company-sponsored IND allows Xiangxue Life Sciences (XLifeSc) to proceed to the next stage of clinical studies in China Encouraging positive clinical safety and efficacy.
- GlobeNewswire•2 months ago
Athenex Announces Expansion of Board of Directors
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the resignation of Sheldon Trainor-De Girolamo as a Director of the company. The company also announces the appointment of two new Directors: John Moore Vierling, MD, FACP, FAASLD, AGAF, tenured Professor of Medicine and Surgery at the Baylor College of Medicine, and Stephanie Davis, Senior Client Partner at Korn Ferry.
- GuruFocus.com•2 months ago
Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $141,240 of Shares
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Warning! GuruFocus has detected 3 Warning Signs with ATNX.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ATNX earnings conference call or presentation 11-Mar-19 12:30pm GMT
Q4 2018 Athenex Inc Earnings Call
- American City Business Journals•2 months ago
The moment Athenex executives and investors have been waiting for is almost here
Results from the Phase 3 study of Athenex's leading drug candidate will be published in the middle of this year, potentially signaling to the world the arrival of its technology.
- GlobeNewswire•2 months ago
SunGen Pharma and Athenex Pharmaceutical Division Announce Busulfan Injection Product Launch
PRINCETON, N.J., March 13, 2019 -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished.
Motley Fool•2 months agoAthenex, Inc. (ATNX) Q4 2018 Earnings Conference Call Transcript
ATNX earnings call for the period ending December 31, 2018.
- Associated Press•2 months ago
Athenex: 4Q Earnings Snapshot
On a per-share basis, the Buffalo, New York-based company said it had a loss of 41 cents. The biopharmaceutical company posted revenue of $21.3 million in the period. For the year, the company reported ...
